Effects of digoxinlike immunoreactive substances and digoxin FAB antibodies on the new digoxin microparticle enzyme immunoassay

Therapeutic Drug Monitoring

Volumn 19, Issue 2, 1997, Pages 185-190

  Crossey, Michael J ^a   Dasgupta, Amitava ^a,b  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO HOSPITAL   (United States)

Author keywords

Digibind; Digoxin; Digoxin like immunoreactive substances; Microparticle Enzyme Immunoassay

Indexed keywords

DIGOXIN; IMMUNOGLOBULIN F(AB) FRAGMENT;

ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DRUG DETERMINATION; ENZYME IMMUNOASSAY; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; PRIORITY JOURNAL; ULTRAFILTRATION;

ANTIBODIES; DIGOXIN; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMANS; IMMUNOENZYME TECHNIQUES; PREGNANCY;

EID: 0031441471     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199704000-00012     Document Type: Article

References (18)

1. Graves AW, Brown BA, Valdes R. Digoxin-like substances in a patient with renal impairment. Ann Intern Med 1983;99:604-8.
2. Nanja AA, Greenway DC. Falsely raised plasma digoxin concentrations in liver disease. Br Med J 1985;290:432-5.
3. Sault MH, Vasdev SC, Longerich LL. Endogenous digoxin-like substances in patients with combined hepatic and renal failure. Ann Intern Med 1984;58:748-51.
4. Graves SW. The possible role of digitalis-like factors in pregnancy induced hypertension. Hypertension 1987;10(suppl 1):184-6.
5. Cloix JF. Endogenous digitalis-like compounds. Hypertension 1987;(suppl 1):67-70.
6. Stone JA, Soldin SL. An update on digoxin. Clin Chem 1989;35: 1326-31.
7. Soldin SJ. Digoxin - issues and controversies. Clin Chem 1986; 32:5-12.
8. Miller JJ, Straub RW, Valdes R. Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS: 180. Ther Drug Monit 1996;18:65-72.
9. Mahdyoon H, Battilana G, Rosman H, Goldstein S, Gheorghiade M. The evolving pattern of digoxin intoxication: observations at a large urban hospital from 1980-1988. Am Heart J 1990;120: 1190-4.
10. Antman EM, Wenger TL, Butler VP, Haber E, Smith TW. Treatment of 150 cases of life threatening digitalis intoxication with digoxin-specific antibody fragment. Circulation 1990;81:1744-52.
11. Ujhelyi MR, Curry RW, Robinson JD. Management of unusually high serum digoxin concentrations. Drug Intell Clin Pharm 1988; 22:345-6.
12. Clifton GD, McIntyre WJ, Zannikos PN, Harrison MR, Chandler MH. Free and total serum digoxin concentrations in a renal failure patient after treatment with digoxin immune fab. Clin Pharm 1988; 8:441-5.
13. Lemon M, Andrews DJ, Binks AM, Georgiou GA. Concentrations of free serum digoxin after treatment with antibody fragment. Br Med J 1987;295:1520-1.
14. Rainey PM. Effects of digoxin immune fab (ovine) on digoxin immunoassays. Am J Clin Pathol 1989;92:779-86.
15. Ujhelyi M, Cummings DM, Green P, Ellison M, Vlasses P. Effect of digoxin fab antibodies on five digoxin immunoassays. Ther Drug Monit 1990;12:288-92.
16. Valdes R, Graves SW. Protein binding of endogenous digoxin-like immunoreactive factor in human serum and its variation with clinical condition. J Clin Endocrinol Metab 1985;60:1135-43.
17. Dasgupta A, Schammel D, Limmany A, Datta P. Estimating concentrations of total digoxin and digoxin like immunoreactive substances in volume expanded patients being treated with digoxin. Ther Drug Monit 1996;18:34-9.
18. Christenson RH, Studenberg SD, Davis SB, Sedor FA. Digoxin-like immunoreactivity eliminated from serum after centrifugal ultrafiltration before fluorescence polarization immunoassay for digoxin. Clin Chem 1987;33:606-8.